Skip to main content
. 2020 Dec 21;2020(12):CD007245. doi: 10.1002/14651858.CD007245.pub4

4. Omar 2010.

  Treatment Group Control P value
12 months follow‐up
Randomised 75 75
Completed 60 63
Abnormal vaginal bleeding or spotting 22 2 <0.001
Breast cancer‐related deaths 0 1 NR
24 months follow‐up
Completed 59 62
Abnormal vaginal bleeding or spotting 7 2 0.08
Endometrial polyps 1 10 0.02
Endometrial hyperplasia 0 0 NA
Fibroids 2 4 1.1

NA: not applicable
NR: not reported